<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29204927</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2190-3948</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery and translational research</Title>
          <ISOAbbreviation>Drug Deliv Transl Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion.</ArticleTitle>
        <Pagination>
          <StartPage>204</StartPage>
          <EndPage>225</EndPage>
          <MedlinePgn>204-225</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13346-017-0453-9</ELocationID>
        <Abstract>
          <AbstractText>The oral bioavailability of felodipine, a dihydropyridine calcium channel antagonist, is about 15%. This may be due to poor water solubility, and a lower intestinal permeability than a BCS class I drug, and hepatic first-pass metabolism of the drug. Many drugs are unpopular due to solubility issues. The goal of this study was to develop and optimize a felodipine-containing microemulsion to improve the intestinal permeability and bioavailability of the drug. The felodipine microemulsions were developed with the selected components, i.e., α-linolenic acid as the oil phase, Tween 80 as a surfactant, and isopropyl alcohol as co-surfactant using Box-Behnken design and characterized for in vitro release and particle size. The optimized felodipine-loaded microemulsion was investigated for physicochemical interaction, surface morphology, intestinal permeability, rheology, cytotoxicity, cellular uptake, pharmacodynamic (electrocardiogram and heart rate variability), and pharmacokinetic studies to explore its suitability as a promising oral drug delivery system for the treatment of hypertension. The optimized felodipine-loaded microemulsion showed significantly higher (P &lt; 0.05) apparent permeability coefficients (Papp) at 7.918 × 10<sup>-5</sup> cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10<sup>-5</sup> cm/s, respectively. The optimized felodipine-loaded microemulsion showed biocompatibility and no cytotoxicity. Cellular uptake studies confirmed payload delivery to a cellular site on the J774.A1 cell line. The rheology study of the optimized felodipine-loaded microemulsion revealed Newtonian-type flow behavior and discontinuous microemulsion formation. In pharmacodynamic studies, significant differences in parameters were observed between the optimized felodipine-loaded microemulsion and marketed formulation. The optimized felodipine-loaded microemulsion showed significantly higher (p &lt; 0.01) C <sub>max</sub> (7.12 ± 1.04 μg/ml) than marketed tablets (2.44 ± 1.03 μg/ml). It was found that AUC<sub>last</sub> obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 μg h/ml) was significantly higher (p &lt; 0.01) than the marketed tablet (27.41 ± 5.54 μg h/ml). The relative bioavailability (Fr) of the optimized felodipine-loaded microemulsion was about 308.3% higher than that of the marketed formulation. The results demonstrate that the prepared microemulsion is an advanced and efficient oral delivery system of felodipine for the management of hypertension.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Mahendra</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanoujia</LastName>
            <ForeName>Jovita</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parashar</LastName>
            <ForeName>Poonam</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arya</LastName>
            <ForeName>Malti</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tripathi</LastName>
            <ForeName>Chandra B</ForeName>
            <Initials>CB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sinha</LastName>
            <ForeName>V R</ForeName>
            <Initials>VR</Initials>
            <AffiliationInfo>
              <Affiliation>University Institute of Pharmaceutical Sciences, Sector-14, Panjab University, Chandigarh, UT, 160014, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saraf</LastName>
            <ForeName>Shailendra K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, B.B.D.N.I.I.T, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saraf</LastName>
            <ForeName>Shubhini A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow, UP, 226025, India. shubhini.saraf@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Drug Deliv Transl Res</MedlineTA>
        <NlmUniqueID>101540061</NlmUniqueID>
        <ISSNLinking>2190-393X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004655">Emulsions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0RBV727H71</RegistryNumber>
          <NameOfSubstance UI="D017962">alpha-Linolenic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007408" MajorTopicYN="N">Intestinal Absorption</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017962" MajorTopicYN="N">alpha-Linolenic Acid</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cellular uptake</Keyword>
        <Keyword MajorTopicYN="Y">Cytotoxicity</Keyword>
        <Keyword MajorTopicYN="Y">Electrocardiogram</Keyword>
        <Keyword MajorTopicYN="Y">Heart rate variability</Keyword>
        <Keyword MajorTopicYN="Y">Microemulsion</Keyword>
        <Keyword MajorTopicYN="Y">α-Linolenic acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29204927</ArticleId>
        <ArticleId IdType="doi">10.1007/s13346-017-0453-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s13346-017-0453-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1988;36(4):387–428. https://doi.org/10.2165/00003495-198836040-00002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003495-198836040-00002</ArticleId>
            <ArticleId IdType="pubmed">3069435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil PR, Biradar SV, Paradkar AR. Extended release felodipine self-nanoemulsifying system. AAPS PharmSciTech. 2009;10(2):515–23. https://doi.org/10.1208/s12249-009-9235-0 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-009-9235-0</ArticleId>
            <ArticleId IdType="pubmed">19415505</ArticleId>
            <ArticleId IdType="pmc">2690798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blychert E, Wingstrand K, Edgar B, Lidman K. Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. Br J Clin Pharmacol. 1990;29(1):39–45. https://doi.org/10.1111/j.1365-2125.1990.tb03600.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.1990.tb03600.x</ArticleId>
            <ArticleId IdType="pubmed">2404502</ArticleId>
            <ArticleId IdType="pmc">1380059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EJ, Chun MK, Jang JS, Lee IH, Lee KR, Choi HK. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm. 2006;64(2):200–5. https://doi.org/10.1016/j.ejpb.2006.04.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2006.04.001</ArticleId>
            <ArticleId IdType="pubmed">16750355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S, Yao T, Zhang X, Gan L, Zhu C, Yu H, et al. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int J Pharm. 2009;379(1):18–24. https://doi.org/10.1016/j.ijpharm.2009.06.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2009.06.001</ArticleId>
            <ArticleId IdType="pubmed">19508887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15(5):405–15. https://doi.org/10.1016/S0928-0987(02)00051-9 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0928-0987(02)00051-9</ArticleId>
            <ArticleId IdType="pubmed">12036717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3):278–87. https://doi.org/10.1016/j.ejps.2006.04.016 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2006.04.016</ArticleId>
            <ArticleId IdType="pubmed">16815001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1–10. https://doi.org/10.1016/j.jconrel.2008.03.021 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2008.03.021</ArticleId>
            <ArticleId IdType="pubmed">18499294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fanun M. Microemulsions as delivery systems. Curr Opin Colloid Interface Sci. 2012;17(5):306–13. https://doi.org/10.1016/j.cocis.2012.06.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cocis.2012.06.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. https://doi.org/10.5402/2012/195727 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22830056</ArticleId>
            <ArticleId IdType="pmc">3399483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box Behnken design and desirability function. Int J Pharm. 2007;332(1):55–63. https://doi.org/10.1016/j.ijpharm.2006.09.060 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2006.09.060</ArticleId>
            <ArticleId IdType="pubmed">17169518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zvonar A, Berginc K, Kristl A. GaÅ¡perlin M. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm. 2010;388(1):151–8. https://doi.org/10.1016/j.ijpharm.2009.12.055 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2009.12.055</ArticleId>
            <ArticleId IdType="pubmed">20060454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay S, Katare OP, Singh B. Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B: Biointerfaces. 2012;100:50–61. https://doi.org/10.1016/j.colsurfb.2012.05.019 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2012.05.019</ArticleId>
            <ArticleId IdType="pubmed">22766282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh M, Kanoujia J, Singh P, Tripathi CB, Arya M, Parashar P, et al. Development of an α-linolenic acid containing soft nanocarrier for oral delivery: in vitro and in vivo evaluation. RSC Adv. 2016;6(81):77590–602. https://doi.org/10.1039/C6RA15166C .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6RA15166C</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rathod SP, Shah N, Balaraman R. Antihypertensive effect of dietary calcium and diltiazem, a calcium channel blocker on experimentally induced hypertensive rats. Indian J Pharmacol. 1997;29(2):99.</Citation>
        </Reference>
        <Reference>
          <Citation>Sahu BP, Das MK. Preparation and in vitro/in vivo evaluation of felodipine nanosuspension. Eur J Drug Metab Pharmacokinet. 2014;39(3):183–93. https://doi.org/10.1007/s13318-013-0158-5 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13318-013-0158-5</ArticleId>
            <ArticleId IdType="pubmed">24198215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm. 2007;345(1):9–25. https://doi.org/10.1016/j.ijpharm.2007.08.057 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2007.08.057</ArticleId>
            <ArticleId IdType="pubmed">17945446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673–91. https://doi.org/10.1016/j.addr.2007.10.014 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2007.10.014</ArticleId>
            <ArticleId IdType="pubmed">18155801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Circulation. 2002;105(16):1897–903. https://doi.org/10.1161/01.CIR.0000014682.14181.F2 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000014682.14181.F2</ArticleId>
            <ArticleId IdType="pubmed">11997274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr Atheroscler Rep. 2003;5(2):139–45. https://doi.org/10.1007/s11883-003-0086-y .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11883-003-0086-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pignier C, Revenaz C, Rauly-Lestienne I, Cussac D, Delhon A, Gardette J, et al. Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current. Basic Res Cardiol. 2007;102(6):553–64. https://doi.org/10.1007/s00395-007-0676-x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00395-007-0676-x</ArticleId>
            <ArticleId IdType="pubmed">17891522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4):39–49. https://doi.org/10.1016/j.amjcard.2005.12.026 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2005.12.026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori TA. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol. 2006;33(9):842–6. https://doi.org/10.1111/j.1440-1681.2006.04451.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1681.2006.04451.x</ArticleId>
            <ArticleId IdType="pubmed">16922818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mozaffarian D. Does alpha-linolenic acid intake reduce the risk of coronary heart disease? A review of the evidence. Altern Ther Health Med. 2005;11(3):24–30; quiz 31, 79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15945135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SK, Prasad Verma PR, Razdan B. Glibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization. Drug Dev Ind Pharm. 2010;36(8):933–45. https://doi.org/10.3109/03639040903585143 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03639040903585143</ArticleId>
            <ArticleId IdType="pubmed">20184416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pal R. Rheology of simple and multiple emulsions. Curr Opin Colloid Interface Sci. 2011;16(1):41–60. https://doi.org/10.1016/j.cocis.2010.10.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cocis.2010.10.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng JL, Wang ZW, Zhang J, Wang ZN, Liu F. Study on food-grade vitamin E microemulsions based on nonionic emulsifiers. Colloids Surf A Physicochem Eng Asp. 2009;339(1):1–6. https://doi.org/10.1016/j.colsurfa.2009.01.002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfa.2009.01.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya DP, Hartley PG. Progress in microemulsion characterization. Curr Opin Colloid Interface Sci. 2012;17(5):274–80. https://doi.org/10.1016/j.cocis.2012.07.002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cocis.2012.07.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89–121. https://doi.org/10.1016/S0169-409X(00)00103-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0169-409X(00)00103-4</ArticleId>
            <ArticleId IdType="pubmed">11104900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, Chavhan S, Sawant KK. Self-nanoemulsifying drug delivery system for adefovir dipivoxil: design, characterization, in vitro and ex vivo evaluation. Colloids Surf A Physicochem Eng Asp. 2011;392(1):145–55. https://doi.org/10.1016/j.colsurfa.2011.09.048 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfa.2011.09.048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009;135(3):259–67. https://doi.org/10.1016/j.jconrel.2009.01.018 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2009.01.018</ArticleId>
            <ArticleId IdType="pubmed">19331853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You X, Xing Q, Tuo J, Song W, Zeng Y, Hu H. Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: just enough or more than enough? Int J Pharm. 2014;471(1):276–84. https://doi.org/10.1016/j.ijpharm.2014.05.031 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2014.05.031</ArticleId>
            <ArticleId IdType="pubmed">24858390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder HA, Vinton WH. Hypertension induced in rats by small doses of cadmium. Am J Physiol Legacy Content. 1962;202(3):515–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Foulke JD, Kessler WV, Born GS, Shaw SM, Vetter RJ. Effect of cadmium on sodium and potassium excretion and on action of hydrochlorothiazide in rats. J Pharm Sci. 1974;63(4):563–6. https://doi.org/10.1002/jps.2600630414 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.2600630414</ArticleId>
            <ArticleId IdType="pubmed">4828705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mutiso SK, Rono DK, Bukachi F. Relationship between anthropometric measures and early electrocardiographic changes in obese rats. BMC Res Notes. 2014;7(1):931. https://doi.org/10.1186/1756-0500-7-931 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-0500-7-931</ArticleId>
            <ArticleId IdType="pubmed">25522784</ArticleId>
            <ArticleId IdType="pmc">4302031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nada A, Gintant GA, Kleiman R, Gutstein DE, Gottfridsson C, Michelson EL, et al. The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development. Am Heart J. 2013;165(4):489–500. https://doi.org/10.1016/j.ahj.2013.01.011 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ahj.2013.01.011</ArticleId>
            <ArticleId IdType="pubmed">23537964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sermuksnien ZR, Kajenien A, Berskien K, Daunoravicien A, Kandratavicien SR. Assessment of the effect of anthropometric data on the alterations of cardiovascular parameters in Lithuanian elite male basketball players during physical load. Medicina. 2012;48(11):566–71.</Citation>
        </Reference>
        <Reference>
          <Citation>Taggart P, Sutton PMI, Opthof T, Coronel R, Trimlett R, Pugsley W, et al. Transmural repolarisation in the left ventricle in humans during normoxia and ischaemia. Cardiovasc Res. 2001;50(3):454–62. https://doi.org/10.1016/S0008-6363(01)00223-1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0008-6363(01)00223-1</ArticleId>
            <ArticleId IdType="pubmed">11376621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease. Circulation. 2009;119(5):663–70. https://doi.org/10.1161/CIRCULATIONAHA.108.797035 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.797035</ArticleId>
            <ArticleId IdType="pubmed">19171855</ArticleId>
            <ArticleId IdType="pmc">2734945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straus SMJM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362–7. https://doi.org/10.1016/j.jacc.2005.08.067 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2005.08.067</ArticleId>
            <ArticleId IdType="pubmed">16412861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe N, Kobayashi Y, Tanno K, Miyoshi F, Asano T, Kawamura M, et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol. 2004;37(3):191–200. https://doi.org/10.1016/j.jelectrocard.2004.02.002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jelectrocard.2004.02.002</ArticleId>
            <ArticleId IdType="pubmed">15286932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowan WH, Campen MJ, Wichers LB, Watkinson WP. Heart rate variability in rodents: uses and caveats in toxicological studies. Cardiovasc Toxicol. 2007;7(1):28–51. https://doi.org/10.1007/s12012-007-0004-6 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12012-007-0004-6</ArticleId>
            <ArticleId IdType="pubmed">17646680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Task Force of The European Society of C. The North American Society of Pacing and Electrophysiology (Membership of the Task Force listed in the Appendix), Heart rate variability Standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996;17:354–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.eurheartj.a014868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldsmith SR. Effect of amlodipine and felodipine on sympathetic activity and baroreflex function in normal humans. Am J Hypertens. 1995;8(9):902–8. https://doi.org/10.1016/0895-7061(95)00163-J .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0895-7061(95)00163-J</ArticleId>
            <ArticleId IdType="pubmed">8541005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James MA, Rakicka H, Panerai RB, Potter JF. Baroreflex sensitivity changes with calcium antagonist therapy in elderly subjects with isolated systolic hypertension. J Hum Hypertens. 1999;13(2):87–95. https://doi.org/10.1038/sj.jhh.1000780 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.jhh.1000780</ArticleId>
            <ArticleId IdType="pubmed">10100056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrier GR, Redondo I, Zhu J, Murphy MG. Differential effects of docosahexaenoic acid on contractions and L-type Ca<sup>2+</sup> current in adult cardiac myocytes. Cardiovasc Res. 2002;54(3):601–10. https://doi.org/10.1016/S0008-6363(02)00275-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0008-6363(02)00275-4</ArticleId>
            <ArticleId IdType="pubmed">12031706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BP Ander CMC, Dupasquier MA, Prociuk GN. Pierce. Polyunsaturated fatty acids and their effects on cardiovascular disease. Exp Clin Cardiol. 2003;8(4):164–72.</Citation>
        </Reference>
        <Reference>
          <Citation>Salonen JT, Salonen R, Ihanainen M, Parviainen M, Seppänen R, Kantola M, et al. Blood pressure, dietary fats, and antioxidants. Am J Clin Nutr. 1988;48(5):1226–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3189209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-leyva D, Bassett CMC, Mccullough R, Pierce GN. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alphalinolenic acid. Can J Cardiol. 2010;26(9):489–96. https://doi.org/10.1016/S0828-282X(10)70455-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0828-282X(10)70455-4</ArticleId>
            <ArticleId IdType="pubmed">21076723</ArticleId>
            <ArticleId IdType="pmc">2989356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res. 2001;42(3):346–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11254745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113–20. https://doi.org/10.1016/S0928-0987(02)00251-8 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0928-0987(02)00251-8</ArticleId>
            <ArticleId IdType="pubmed">12594003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu L, Wu H, Niu F, Yan C, Yang X, Jia Y. Design of fenofibrate microemulsion for improved bioavailability. Int J Pharm. 2011;420(2):251–5. https://doi.org/10.1016/j.ijpharm.2011.08.043 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2011.08.043</ArticleId>
            <ArticleId IdType="pubmed">21907776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma G, Wilson K, Van der Walle CF, Sattar N, Petrie JR, Kumar MNVR. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm. 2010;76(2):159–69. https://doi.org/10.1016/j.ejpb.2010.07.002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2010.07.002</ArticleId>
            <ArticleId IdType="pubmed">20655382</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
